IPO fever is sweeping through the psychedelics space.
IPO fever is sweeping through the psychedelics space.
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.
Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.
MindMed Inc has applied to up-list on the NASDAQ.
The road to psychedelic drug success leads through functional mushrooms.
Canada stands out as the premier destination for psychedelic drug companies.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now